The role of immunotherapy in resectable non-small-cell lung cancer
Therapeutic Advances in Medical Oncology · 2025-08 · 17
DOI: 10.1177/17588359251361883 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 22.08.2025. Verfasst von Conor D Moloney und 1 weiteren Autor:innen. Beteiligte Einrichtung: Beaumont RCSI Cancer Centre, Dublin, V09 V2N0, Ireland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-small-cell lung cancer (NSCLC) accounts for 80%–85% of all lung cancer cases, being the leading cause of cancer-related mortality worldwide. Historically, outcomes for patients with resectable disease have trailed those with other solid organ malignancies. Advances in treatment strategies, particularly in immunotherapy (IO), have revolutionised the landscape of lung cancer care. In resectable NSCLC (rNSCLC), including stage III disease, the integration of immunotherapy is increasingly being explored for its potential to reduce recurrences and improve survival outcomes. Several landmark clinical trials have resulted in regulatory approvals, and the rapid adoption of immunotherapy in the neoadjuvant, perioperative and adjuvant settings. This review will comprehensively examine the evolving role of immunotherapy in rNSCLC, with a focus on trial evidence, mechanisms of action, biomarkers and challenges in clinical implementation. We also discuss its implications for multimodal therapy across neoadjuvant, perioperative and adjuvant settings while highlighting potential future directions and identifying unanswered questions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beaumont RCSI Cancer Centre, Dublin, V09 V2N0, Ireland.
- Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, D08 XF38, Ireland.
ORCID-Profile: Conor D Moloney
Zitieren
APA
Moloney, C. D., & Forde, P. M. (2025). The role of immunotherapy in resectable non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359251361883
Vancouver
Moloney CD, Forde PM. The role of immunotherapy in resectable non-small-cell lung cancer. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359251361883
BibTeX
@article{Moloney2025,
author = {Moloney, Conor D and Forde, Patrick M},
title = {The role of immunotherapy in resectable non-small-cell lung cancer},
journal = {Therapeutic Advances in Medical Oncology},
year = {2025},
volume = {17},
doi = {10.1177/17588359251361883}
}
EUVIMED